High-Level Overview
Positive Development is a Series C-stage healthcare technology company founded in 2019 that provides family-centered, play-based developmental therapy for children with autism and neurodivergent needs.[1][2][5] It offers integrated services including speech therapy, occupational therapy, mental health therapy, and Developmental Relationship-Based Interventions (DRBI), positioning itself as an alternative to traditional Applied Behavior Analysis (ABA) therapy by emphasizing individualized, home-based care that fosters emotional regulation, communication, social engagement, and daily living skills.[1][2][5] Serving about 1,200 clients across 23 service areas in eight states with 850 employees, the company has raised over $123M in funding, including a $51.5M Series C in August 2025 led by aMoon Fund, B Capital, and Flare Capital Partners, fueling expansion via payer partnerships, new markets, and its internal tech platform Stanley.[2][3]
The company targets families of neurodivergent children, delivering care at home with fewer hours (versus ABA's 30+ weekly) to build parent-child connections through play, promising cost savings, better outcomes, and scalability as the largest DRBI provider.[2][4][5] Recent growth includes leadership hires like a Chief Clinical Officer and CFO in July 2024, new centers in New Jersey, and ambitions to triple its client base.[1][2]
Origin Story
Positive Development was founded in 2019 in Monrovia, California (now headquartered in McLean, Virginia), initially under the name Principled Ventures.[1][3] While specific founder details are not publicly detailed in available sources, CEO Mike Suiters has led its evolution into a scaled autism care provider, emphasizing a developmental model that respects each child's neurotype, strengths, and processing style over compliance-based approaches.[2][5]
The idea emerged amid gaps in traditional ABA therapy, which often requires intensive sessions away from home; Positive Development pivoted to DRBI, integrating play-based therapies at home for relational growth.[2][5] Early traction built through de novo tech tools and payer-focused narratives on outcomes and costs, culminating in $72M raised by mid-2025 (pre-$51.5M round) and rapid expansion to eight states by August 2025.[1][2]
Core Differentiators
- Developmental Relationship-Based Intervention (DRBI) Model: Unlike ABA's behavior-compliance focus, Positive Development uses play-based, individualized therapy at home, integrating speech, occupational, and mental health services for holistic growth in under 30 hours weekly, with many children showing gains in six months.[2][5]
- Family-Centered and Home-Based Delivery: Emphasizes parent involvement with 1:1 clinical expert support, building safe connections and recognizing child cues, contrasting clinic-heavy models and boosting long-term outcomes.[5]
- Tech-Enabled Scalability: Proprietary platform Stanley supports operations, payer partnerships (Medicaid/commercial), and alternative payment models; claims cost savings and superior outcomes via data-driven tools.[2]
- Provider Scale and Network: Largest DRBI provider with 850 clinicians across 23 areas in eight states, recent expansions like New Jersey centers, and strong VC backing from B Capital, Flare Capital, and aMoon Fund.[1][2][4]
Role in the Broader Tech Landscape
Positive Development rides the surging demand for neurodiversity-affirming autism care amid rising diagnoses (1 in 36 U.S. children) and criticism of ABA's intensity and efficacy.[2] Its timing aligns with payer shifts toward value-based models favoring outcomes over volume, enabling Medicaid/commercial partnerships and cost-conscious scaling in a $3B+ U.S. autism therapy market.[2]
Market forces like telehealth adoption post-COVID, tech integration in healthcare, and VC interest in "high-impact" healthtech propel its growth, positioning it as a disruptor to fragmented ABA providers.[2][4] By influencing ecosystems through scaled DRBI, payer innovations, and family empowerment, it advocates for accommodations over "fixing" neurotypes, potentially reshaping standards toward relational, tech-supported care.[5]
Quick Take & Future Outlook
Positive Development is primed to dominate developmental autism therapy, leveraging its $51.5M raise to triple clients via market deepening, payer models, and Stanley platform enhancements.[2] Trends like AI-driven personalization in healthtech, neurodiversity movements, and capitated payments will accelerate its edge, though scaling clinician quality and regulatory hurdles in Medicaid loom as risks.
As the alternative to ABA gains traction, expect Positive Development to influence policy and ecosystems, empowering more families—echoing its mission to turn play into lifelong high achievement from day one.[5]
